– Dr. John Mendlein Transitions from CEO to Non-Executive Board Member,
Dr. Sanjay Shukla Appointed President and CEO –
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery
and development of immunology-based protein therapeutics to treat patients suffering from severe, rare immune-mediated diseases, as
well as various cancers, announced that today Sanjay Shukla, M.D., M.S., who joined aTyr Pharma as Chief Medical Officer in March
2016, will succeed John Mendlein, Ph.D., as President and Chief Executive Officer. Dr. Shukla will also join aTyr’s Board of
Directors. Dr. Mendlein, who has served as Chief Executive Officer since September 2011 and as a member of the Board of Directors
since July 2010, will continue to serve on the Board of Directors of aTyr Pharma.
“This is an excellent time for aTyr as we are well-positioned for future growth with strong leadership to drive forward our
shared vision to develop meaningful medicines for patients with rare muscle and lung diseases, as well as to serve cancer patients
with products based on our new immuno-oncology platform, ORCA,” said John Mendlein, outgoing-CEO of aTyr Pharma. “After six
incredible years as CEO, I am very pleased to pass the leadership torch to Sanjay and continue to advise him as a board member.
Having worked extensively with Sanjay, I am confident he will continue to elevate aTyr to greater heights for patients and all
stakeholders alike. I would like to express my immense gratitude to all our amazing employees, board, patients, and investors for
all that we have accomplished so far at aTyr.”
“We are truly grateful for John’s leadership in guiding aTyr through several key milestones, including bringing the first
Physiocrine-based therapeutic into the clinic, building a well-capitalized, NASDAQ-traded company, growing a robust pipeline of
three biologic programs and solidifying aTyr’s intellectual property estate for an entire new class of proteins,” said John Clarke,
chairman of aTyr Pharma’s board. “We thank John for his leadership and accomplishments at aTyr and wish him well in all his future
endeavors. Looking forward, we are excited about this transition and confident that under Sanjay’s leadership, aTyr will continue
to grow and successfully deliver upon its important mission.”
Dr. Shukla will continue aTyr’s mission to develop innovative new protein therapeutics based on its knowledge of Physiocrine
biology. Dr. Shukla served as aTyr’s Chief Medical Officer since March 2016 and has over twenty years of leadership experience in
both large pharma and biotech companies. Since joining aTyr, Dr. Shukla led the completion of three Phase 1b/2 Resolaris™ clinical
trials and two long-term safety extension studies for the treatment of rare muscular dystrophies and has advanced the iMod.Fc
program for the treatment of interstitial lung diseases towards the clinic with a Phase 1 trial expected to commence this
quarter.
“I am excited for the opportunity to lead aTyr at such a productive time for the company,” said Sanjay Shukla, President and CEO
of aTyr Pharma. “Our team has made tremendous progress in elucidating the biology and laying the groundwork for the potential
therapeutic applications of this groundbreaking new science, under John’s leadership. I am ready to lead our team forward to
continue to build on this strong foundation of success. Our mission remains steadfast and during this quarter we intend to bring a
second Physiocrine-based therapeutic candidate into the clinic with an iMod.Fc Phase 1 trial and select an antibody to develop as
an IND candidate from our ORCA program.”
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients using its knowledge of
Physiocrine biology, a newly discovered set of immunological and physiological pathways. To date, aTyr has generated three
innovative therapeutic programs with three different biologic modalities based on its knowledge of the Resokine pathway to treat
patients suffering from severe, rare immune-mediated diseases, as well as various cancers. The Resolaris and iMod.Fc programs are
agonists of the Resokine pathway designed to temper immune system engagement in diseases characterized by excessive immune cell
involvement. aTyr’s third program, ORCA, represents a novel, proprietary pathway in immuno-oncology that utilizes antibody
approaches to block the Resokine pathway and ‘release multiple brakes’ on the immune system in the tumor cell environment. aTyr has
built an intellectual property estate, to protect its pipeline, comprising over 220 issued patents or allowed patent applications
that are owned or exclusively licensed, including over 300 potential Physiocrine-based protein compositions. For more information,
please visit http://www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act.
Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,”
“intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend
these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this
statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements
regarding the timing of our clinical trials and IND candidate selection and the scope and strength of our intellectual property
portfolio reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the
information currently available to us and on assumptions we have made. Although we believe that our plans, intentions,
expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give
no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may
differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors
that are beyond our control including, without limitation, risks associated with the discovery, development and regulation of our
Physiocrine-based product candidates, the risk that we may cease or delay preclinical or clinical development activities for any of
its existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in
planned clinical trials), and the risk that we may not be able to raise the additional funding required for its business and
product development plans, as well as those set forth in our most recent Annual Report on Form 10-K for the year ended December 31,
2016 and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking
statements, whether as a result of new information, future events or otherwise.
Contact:
Mark Johnson
Sr. Director, Investor Relations
mjohnson@atyrpharma.com
858-223-1163
